CAS: 16730-20-4; 5-Nitro-1H-Indole-2-Carboxylic Acid

相似化合物

16732-57-3 10242-00-9 6960-45-8

上下游产品

CAS号16732-57-3 5-硝基吲哚-2-甲酸乙酯 | CAS号71056-94-5 1-甲基-5-硝基-1H-吲哚-2-羧酸 | CAS号157649-56-4 5-硝基-1H-吲哚-2-羧酸甲酯 | CAS号73647-04-8 2-[2-(4-硝基苯基)亚肼... | CAS号100-01-6 对硝基苯胺 | CAS号63190-15-8 (Z)-ethyl 2-(p-... | CAS号99-61-6 间硝基苯甲醛 | CAS号6146-52-7 5-硝基吲哚 | CAS号5192-03-0 5-氨基吲哚 | CAS号157649-56-4 5-硝基-1H-吲哚-2-羧酸甲酯 | CAS号152213-40-6 5-氨基-2-吲哚羧酸 | CAS号71056-94-5 1-甲基-5-硝基-1H-吲哚-2-羧酸

1-甲基-5-硝基吲哚-2-羧酸置于水,Tin(Ll) Chloride体系中,用 Dmf (N,N-Dimethyl-Formamide) 用作溶剂,化学反应 3.0H,反应生成5-硝基吲哚-2-甲酸
参考文献: Viral Polymerase Inhibitors[fr] Inhibiteurs De Polymerase Virale
标题: Viral Polymerase Inhibitors[fr] Inhibiteurs De Polymerase Virale
摘要:化合物的异构体,对映体,非对映异构体或互变异构体,由式(I)所代表:其中a,B,R2,R3,L,M1,M2,M3,M4,Y1,Y0,Z和sp如权利要求1中定义,或其盐,作为hcv Ns5B聚合酶的抑制剂.

专利信息

专利号:US-7329760-B2
优先权日:2002-04-05
标题 :CC-1065 analog synthesis
发明人：ZHAO ROBERT YONGXIN; CHARI RAVI V J
权利人:IMMUNOGEN INC
摘要:Improved synthesis of seco(−)CBI (5-hydroxy-3-amino-1-[S]-(chloromethyl)-1,2-dihydro-3H-benz(e)indole): n nand improved syntheses therefrom of a wide variety of CC-1065 analogs that comprise a cyclopropabenzidole (CBI) alkylating moiety, and which are collectively DC1 and its derivatives, for the synthesis of cell-targeted therapeutic agents.

专利号:JP-2005522506-A
优先权日:2002-04-05
标 题 :Improved synthesis of CC-1065 related substances

专利号:ES-2286418-T3
优先权日:2002-04-05
标 题 :IMPROVED SYNTHESIS OF ANALOGS OF CC-1065.

专利号:PT-1492766-E
优先权日:2002-04-05
标题 :IMPROVED SYNTHESIS OF CC-1065 ANALOGS.

专利号:EP-1492766-A4
优先权日:2002-04-05
标 题 :IMPROVED SYNTHESIS OF CC-1065 ANALOGUE

专利号:US-8513241-B2
优先权日:2008-03-28
标题 :3,4-dihydro-2H-pyrazino[1,2-A]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
发明人：CERVI GIOVANNI; D ANELLO MATTEO; PAPEO GIANLUCA MARIANO ENRICO; SALOM BARBARA
权利人:CERVI GIOVANNI; D ANELLO MATTEO; PAPEO GIANLUCA MARIANO ENRICO; SALOM BARBARA; NERVIANO MEDICAL SCIENCES SRL
摘要:Compounds which are 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, viral infection, prevention of AIDS development in HIV-infected individuals, cell proliferative disorders, autoimmune and neurodegenerative disorders; also disclosed is a process under Solid Phase Synthesis conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them.